Matthew A. Powell, MD, reviews recent advances in the treatment of patients with endometrial carcinoma, referencing several key clinical trials and real-world datasets.
EP. 1: Recommended Biomarker Testing in Patients With Endometrial Cancer
Medical expert provides an overview of the recommended biomarker testing for endometrial cancer and the frontline treatment options available for patients with dMMR/MSI-high endometrial cancer.
EP. 2: Dostarlimab in Combination with Carboplatin and Paclitaxel for Treatment of dMMR Endometrial Cancer
Dr Matthew A. Powell reviews the study design and key endpoints of the RUBY trial in dMMR endometrial cancer and explains the potential clinical implications of the data.
EP. 3: Overview of the Systemic Treatment Options for Metastatic or Relapsed Endometrial Cancer
Matthew A. Powell, MD, shares an overview of the systemic treatment options for patients with relapsed or metastatic endometrial cancer and the factors he considers when selecting an appropriate frontline therapy.
EP. 4: Rationale for Treatment Strategies with Single Agent IO in Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
Dr Matthew A. Powell details the rationale for using single-agent immunotherapy treatments for patients with advanced or recurrent endometrial cancer with reference to data updates from several key clinical trials.
EP. 5: Treatment With Combination Lenvatinib Plus Pembrolizumab in Patients With Recurrent Endometrial Cancer
Matthew A. Powell, MD, reviews key takeaways from the Study-309/KEYNOTE-775 trial investigating lenvatinib plus pembrolizumab for the treatment for endometrial cancer.
EP. 6: Emerging Combination Treatments for Patients With Endometrial Cancer
Dr Matthew A. Powell shares some closing thoughts on emerging agents and combination therapies in the endometrial cancer treatment landscape.
2 Clarke Drive Cranbury, NJ 08512